seRNA 004

About SRTD biotech

SRTD Biotech is a private, preclinical-stage biotech developing a proprietary 'RNA pro-drug' platform termed seRNA (selectively expressed RNA). The technology merges RNA interference for cell-specific targeting with mRNA for effector molecule expression, delivered via proprietary lipid nanoparticles (fLNPs). The company's initial pipeline focuses on oncology (HCC, glioblastoma, lung cancer), with plans to expand into viral and autoimmune diseases, aiming to overcome the off-target side effects common to many existing therapies.

Therapeutic Areas

Other Viral Diseases Drugs